Developer docs
API playgroundTry for free, no card

Search company profiles

Exicure

Full company profile

uuid0002qho

Namestring
Exicure
Legal namestring
Exicure, Inc.
Websiteurl
exicuretx.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Exicure, Inc. is a publicly traded clinical-stage biotechnology company (NASDAQ: XCUR) headquartered in Wilmington, Delaware, that develops immunomodulatory and gene-regulating drug candidates, with its current strategic focus on GPCR-targeted therapeutics. Its lead asset is Burixafor (GPC-100/TG-0054), a CXCR4 antagonist that mobilizes hematopoietic progenitor cells within approximately one hour of administration — markedly faster than the 10–14 hours typical of approved CXCR4 inhibitors — and is being advanced for stem cell mobilization in multiple myeloma autologous transplantation, as well as combination regimens in sickle cell disease, acute myeloid leukemia, and solid tumors. The company acquired GPCR Therapeutics USA Inc. in January 2025 to bring the Burixafor program and a broader GPCR platform in-house, while retaining a legacy Spherical Nucleic Acid (SNA) gene-regulation technology that is no longer the primary strategic focus.

Exicure operates as a pre-revenue, clinical-stage biotech with no commercial products; its economics are driven by R&D funded through equity issuances, including an $11.5 million registered direct offering in December 2021 and a February 2023 private placement that made CBI USA, Inc. the majority shareholder at approximately 50.4% ownership. The company monetizes through future drug commercialization, licensing, or partnership economics contingent on regulatory approval of its clinical assets. Its go-to-market runs through enterprise partnerships (notably Adbiotech Co., Ltd. for co-development in Asia), clinical trial sites at transplant centers and hematology/oncology clinics globally, and scientific dissemination via conferences (ASH, Tandem Meetings) and peer-reviewed publications. End users are hematology and oncology patients, particularly those with multiple myeloma requiring autologous stem cell transplantation.

The business is presently under significant operational and financial stress. Cash declined from approximately $12.5 million at the end of 2024 to roughly $3.7 million at year-end 2025 and approximately $2.1 million as of Q1 2026, and the company received Nasdaq notifications in May–June 2026 regarding delayed quarterly filings and failure to maintain the $2.5 million minimum stockholders' equity requirement. The CEO, CFO, and multiple board members resigned in February–March 2026 with no announced executive successors. Despite these challenges, Phase 2 data reported at the 2025 ASH Annual Meeting showed approximately 90% of multiple myeloma participants meeting the primary endpoint of target stem cell collection within two leukapheresis sessions, and Burixafor carries Orphan Drug Designation, providing regulatory exclusivity incentives for the indication.

Short descriptiontext

Exicure is a publicly traded, pre-revenue clinical-stage biotechnology company (NASDAQ: XCUR) developing GPCR-targeted therapeutics, with lead asset Burixafor — a CXCR4 inhibitor that mobilizes stem cells in one hour for multiple myeloma and other hematologic and solid tumor indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, GPCR-targeted therapeutics, CXCR4 inhibitor drugs, stem cell mobilization, hematologic oncology drugs
Industry1 code
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biotechnology / Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing proprietary drugs. Revenue will be generated through drug commercialization, licensing deals, and potential partnership payments upon regulatory approval.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Exicure is a clinical-stage biotechnology company developing GPCR-targeted therapeutics, with its lead candidate Burixafor (GPC-100/TG-0054), a CXCR4 inhibitor designed for rapid stem cell mobilization in patients undergoing autologous hematopoietic cell transplantation for hematologic malignancies such as multiple myeloma. The company acquired GPCR Therapeutics USA Inc. in January 2025, expanding its pipeline and R&D capabilities in G-Protein Coupled Receptor-based drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 92% of participants (11/12) met primary endpoint of collecting target stem cells within two leukapheresis sessions
+2 more records
Product overview1 text field

Exicure is a clinical-stage biotechnology company developing a focused pipeline centered on GPCR-targeted therapeutics. The core product is Burixafor (GPC-100/TG-0054), a CXCR4 inhibitor for stem cell mobilization in hematologic malignancies, offered both as monotherapy and in combination with propranolol. The company acquired GPCR Therapeutics USA Inc. in January 2025, expanding its pipeline and R&D capabilities. Legacy SNA technology for gene regulation remains in the portfolio but is not the primary strategic focus.

Product and service2 records
1Burixafor (GPC-100/TG-0054)
CategoryCore product / Oncology drug candidate
Description

A CXCR4 inhibitor and stem cell mobilizer for hematopoietic progenitor cell collection in patients with multiple myeloma undergoing autologous transplantation. Achieves peak stem cell mobilization within one hour of administration compared to 10-14 hours for currently approved CXCR4 inhibitors.

2Burixafor + Propranolol (GPC-100)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Exicure entered a co-development agreement with Korea-based Adbiotech Co., Ltd. (KOSDAQ: 179530) to explore combination therapies based on Burixafor (GPC-100) for sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech conducts in vivo studies and preclinical validation while Exicure provides Burixafor and leads clinical and regulatory strategy. The parties intend to advance selected programs into IND-enabling studies and clinical trials.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

In January 2025, Exicure acquired GPCR Therapeutics USA Inc. to expand its GPCR-targeted therapeutics capabilities. The acquisition brought the Burixafor (GPC-100/TG-0054) asset into Exicure's pipeline and added R&D capabilities. A $1 million payment was triggered upon completion of Phase 2 trial milestone.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing motixafortide (CXCR4 antagonist) for stem cell mobilization in multiple myeloma—the closest direct competitor to Exicure's Burixafor in the same mechanism, indication, and clinical-stage biopharmaceutical space.

TypeBroad incumbent
Description

Clinical-stage biotech focused on hematologic malignancies and conditioning regimens for bone marrow transplantation, with a comparable scale, public-company structure, and indications adjacent to Exicure's MM and AML transplant-mobilization programs.

TypeDirect peer
Description

Developed CXCR4 antagonists and conditioning regimens for stem cell mobilization and transplant, directly comparable in target, therapeutic area, and clinical-stage biotech model despite its winding-down status.

TypeDirect peer
Description

Small-cap clinical-stage oncology biotech listed on Nasdaq, comparable in size, clinical development stage, and hematology/oncology focus, with similar partnership-driven business model and significant reliance on capital markets financing.

TypeDirect peer
Description

Clinical-stage biotech with oncology and cell therapy assets targeting hematologic malignancies, closely comparable in pipeline stage, financing history, and the need for partnerships to advance through pivotal development.

TypeDirect peer
Description

Clinical-stage Nasdaq-listed biotech developing therapies for hematologic malignancies and solid tumors, similar in pre-revenue status, capital-raising dependency, and strategic pivot patterns to Exicure.

TypeDirect peer
Description

Clinical-stage oncology biotech with similar small public-company dynamics, working in indications adjacent to Exicure's pipeline and facing the same imperative to land a partnership or strategic transaction to fund development.

TypeBroad incumbent
Description

Markets Mozobil (plerixafor), the incumbent CXCR4 inhibitor for stem cell mobilization, defining the standard of care that Exicure's Burixafor must displace or differentiate against in multiple myeloma and other transplant settings.

TypeDirect peer
Description

Develops mavorixafor, an oral CXCR4 antagonist approved for WHIM syndrome and being studied across additional immunology and rare-disease indications—the only approved CXCR4 antagonist new entrant with overlapping mechanism to Burixafor.

TypeDirect peer
Description

Clinical-stage oncology biotech with a comparable small-cap, public-company profile, partnered and licensing-driven development model, and a dependency on capital markets consistent with Exicure's structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exicure

Clinical-Stage Biotechnology / Oncology Therapeuticsexicuretx.com

Exicure is a publicly traded, pre-revenue clinical-stage biotechnology company (NASDAQ: XCUR) developing GPCR-targeted therapeutics, with lead asset Burixafor — a CXCR4 inhibitor that mobilizes stem cells in one hour for multiple myeloma and other hematologic and solid tumor indications.

What Exicure does

Exicure, Inc. is a publicly traded clinical-stage biotechnology company (NASDAQ: XCUR) headquartered in Wilmington, Delaware, that develops immunomodulatory and gene-regulating drug candidates, with its current strategic focus on GPCR-targeted therapeutics. Its lead asset is Burixafor (GPC-100/TG-0054), a CXCR4 antagonist that mobilizes hematopoietic progenitor cells within approximately one hour of administration — markedly faster than the 10–14 hours typical of approved CXCR4 inhibitors — and is being advanced for stem cell mobilization in multiple myeloma autologous transplantation, as well as combination regimens in sickle cell disease, acute myeloid leukemia, and solid tumors. The company acquired GPCR Therapeutics USA Inc. in January 2025 to bring the Burixafor program and a broader GPCR platform in-house, while retaining a legacy Spherical Nucleic Acid (SNA) gene-regulation technology that is no longer the primary strategic focus.

Exicure operates as a pre-revenue, clinical-stage biotech with no commercial products; its economics are driven by R&D funded through equity issuances, including an $11.5 million registered direct offering in December 2021 and a February 2023 private placement that made CBI USA, Inc. the majority shareholder at approximately 50.4% ownership. The company monetizes through future drug commercialization, licensing, or partnership economics contingent on regulatory approval of its clinical assets. Its go-to-market runs through enterprise partnerships (notably Adbiotech Co., Ltd. for co-development in Asia), clinical trial sites at transplant centers and hematology/oncology clinics globally, and scientific dissemination via conferences (ASH, Tandem Meetings) and peer-reviewed publications. End users are hematology and oncology patients, particularly those with multiple myeloma requiring autologous stem cell transplantation.

The business is presently under significant operational and financial stress. Cash declined from approximately $12.5 million at the end of 2024 to roughly $3.7 million at year-end 2025 and approximately $2.1 million as of Q1 2026, and the company received Nasdaq notifications in May–June 2026 regarding delayed quarterly filings and failure to maintain the $2.5 million minimum stockholders' equity requirement. The CEO, CFO, and multiple board members resigned in February–March 2026 with no announced executive successors. Despite these challenges, Phase 2 data reported at the 2025 ASH Annual Meeting showed approximately 90% of multiple myeloma participants meeting the primary endpoint of target stem cell collection within two leukapheresis sessions, and Burixafor carries Orphan Drug Designation, providing regulatory exclusivity incentives for the indication.

Exicure firmographics

Firmographics
Name
Exicure
Legal name
Exicure, Inc.
Website
https://exicuretx.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Exicure is a publicly traded, pre-revenue clinical-stage biotechnology company (NASDAQ: XCUR) developing GPCR-targeted therapeutics, with lead asset Burixafor — a CXCR4 inhibitor that mobilizes stem cells in one hour for multiple myeloma and other hematologic and solid tumor indications.
Ownership category
akta.pro rank

Exicure industry classification

Industry
Product category
Clinical-Stage Biotechnology / Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Clinical-stage biotechnology
  • GPCR-targeted therapeutics
  • CXCR4 inhibitor drugs
  • Stem cell mobilization
  • Hematologic oncology drugs

Where Exicure is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Exicure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company developing proprietary drugs. Revenue will be generated through drug commercialization, licensing deals, and potential partnership payments upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Exicure product offering

Product offering

Core offering

Exicure is a clinical-stage biotechnology company developing GPCR-targeted therapeutics, with its lead candidate Burixafor (GPC-100/TG-0054), a CXCR4 inhibitor designed for rapid stem cell mobilization in patients undergoing autologous hematopoietic cell transplantation for hematologic malignancies such as multiple myeloma. The company acquired GPCR Therapeutics USA Inc. in January 2025, expanding its pipeline and R&D capabilities in G-Protein Coupled Receptor-based drug development.

Product overview

Exicure is a clinical-stage biotechnology company developing a focused pipeline centered on GPCR-targeted therapeutics. The core product is Burixafor (GPC-100/TG-0054), a CXCR4 inhibitor for stem cell mobilization in hematologic malignancies, offered both as monotherapy and in combination with propranolol. The company acquired GPCR Therapeutics USA Inc. in January 2025, expanding its pipeline and R&D capabilities. Legacy SNA technology for gene regulation remains in the portfolio but is not the primary strategic focus.

Differentiator

Problem solved

Functional benefit

Products and services

  • Burixafor (GPC-100/TG-0054) A CXCR4 inhibitor and stem cell mobilizer for hematopoietic progenitor cell collection in patients with multiple myeloma undergoing autologous transplantation. Achieves peak stem cell mobilization within one hour of administration compared to 10-14 hours for currently approved CXCR4 inhibitors.
  • Burixafor + Propranolol (GPC-100)

Quantifiable outcome

  • 92% of participants (11/12) met primary endpoint of collecting target stem cells within two leukapheresis sessions
  • +2 more outcomes

Companies that use Exicure

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Exicure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Exicure partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Adbiotech Co., Ltd.coreStrategic or Co-development Partner · 22 April 2026Exicure entered a co-development agreement with Korea-based Adbiotech Co., Ltd. (KOSDAQ: 179530) to explore combination therapies based on Burixafor (GPC-100) for sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech conducts in vivo studies and preclinical validation while Exicure provides Burixafor and leads clinical and regulatory strategy. The parties intend to advance selected programs into IND-enabling studies and clinical trials.
  • GPCR Therapeutics Inc.coreTechnology or Integration · 1 January 2025In January 2025, Exicure acquired GPCR Therapeutics USA Inc. to expand its GPCR-targeted therapeutics capabilities. The acquisition brought the Burixafor (GPC-100/TG-0054) asset into Exicure's pipeline and added R&D capabilities. A $1 million payment was triggered upon completion of Phase 2 trial milestone.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Exicure competitors and assessment

Company assessment

Direct peers

  • BioLineRx: Clinical-stage biopharmaceutical company developing motixafortide (CXCR4 antagonist) for stem cell mobilization in multiple myeloma—the closest direct competitor to Exicure's Burixafor in the same mechanism, indication, and clinical-stage biopharmaceutical space.
  • Magenta Therapeutics: Developed CXCR4 antagonists and conditioning regimens for stem cell mobilization and transplant, directly comparable in target, therapeutic area, and clinical-stage biotech model despite its winding-down status.
  • SELLAS Life Sciences: Small-cap clinical-stage oncology biotech listed on Nasdaq, comparable in size, clinical development stage, and hematology/oncology focus, with similar partnership-driven business model and significant reliance on capital markets financing.
  • Coeptis Therapeutics: Clinical-stage biotech with oncology and cell therapy assets targeting hematologic malignancies, closely comparable in pipeline stage, financing history, and the need for partnerships to advance through pivotal development.
  • Cyclacel Pharmaceuticals: Clinical-stage Nasdaq-listed biotech developing therapies for hematologic malignancies and solid tumors, similar in pre-revenue status, capital-raising dependency, and strategic pivot patterns to Exicure.
  • Aprea Therapeutics: Clinical-stage oncology biotech with similar small public-company dynamics, working in indications adjacent to Exicure's pipeline and facing the same imperative to land a partnership or strategic transaction to fund development.
  • X4 Pharmaceuticals: Develops mavorixafor, an oral CXCR4 antagonist approved for WHIM syndrome and being studied across additional immunology and rare-disease indications—the only approved CXCR4 antagonist new entrant with overlapping mechanism to Burixafor.
  • GT Biopharma: Clinical-stage oncology biotech with a comparable small-cap, public-company profile, partnered and licensing-driven development model, and a dependency on capital markets consistent with Exicure's structure.

Broad incumbents

  • Actinium Pharmaceuticals: Clinical-stage biotech focused on hematologic malignancies and conditioning regimens for bone marrow transplantation, with a comparable scale, public-company structure, and indications adjacent to Exicure's MM and AML transplant-mobilization programs.
  • Genzyme (Sanofi): Markets Mozobil (plerixafor), the incumbent CXCR4 inhibitor for stem cell mobilization, defining the standard of care that Exicure's Burixafor must displace or differentiate against in multiple myeloma and other transplant settings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Exicure social profiles

Digital presence

Exicure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exicure leadership team

Management profile

Number of profiles

Exicure subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Exicure funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exicure M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exicure

What does Exicure do?

Exicure is a clinical-stage biotechnology company developing GPCR-targeted therapeutics, with its lead candidate Burixafor (GPC-100/TG-0054), a CXCR4 inhibitor designed for rapid stem cell mobilization in patients undergoing autologous hematopoietic cell transplantation for hematologic malignancies such as multiple myeloma. The company acquired GPCR Therapeutics USA Inc. in January 2025, expanding its pipeline and R&D capabilities in G-Protein Coupled Receptor-based drug development.

Is Exicure a public or private company?

Exicure is a public company. It is classified as corporate owned and is currently operating.

When was Exicure founded?

Exicure was founded in 2009. It employs 1 to 10 people.

Where is Exicure based?

Exicure is headquartered in Chicago, United States, in the North America region.

How does Exicure make money?

One revenue line is on record: drug Development and Commercialization.

Who are Exicure's main competitors?

Direct peers on record are BioLineRx, Magenta Therapeutics, SELLAS Life Sciences, Coeptis Therapeutics, Cyclacel Pharmaceuticals, Aprea Therapeutics, X4 Pharmaceuticals and GT Biopharma. Broad incumbents are Actinium Pharmaceuticals and Genzyme (Sanofi).

Does Exicure have an API?

No public API is recorded for Exicure.

What industry is Exicure in?

Exicure's product category is Clinical-Stage Biotechnology / Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewExicure Expands into Parkinson’s Devices with Proposed NeuroQ InvestmentExicure announced a proposed investment in NeuroQ to expand into Parkinson's disease devices, offering a 20-100% equity stake via share exchange. It also plans to fund up to $500,000 for X-CUE development and clinical evaluation, with NeuroQ leading the effort.TradingViewExicure (XCUR) Plans NeuroQ Stake and Up to $500K for X-CUEExicure agreed to acquire 20% to 100% of NeuroQ, primarily through Exicure shares, with terms subject to further agreements and approvals. The company plans to provide up to $500K for X-CUE development, with clinical evaluation anticipated to take about six months.TradingViewExicure, Inc. (XCUR) Expects 10-Q Filing Within Five-Day ExtensionExicure filed a Form 12b-25 notice for its 10-Q covering the quarter ended September 30, 2026, citing additional time to review accounting for certain assets and liabilities. It expects to file within the five-day extension period. The filing delay creates reporting uncertainty, and the release provides no details on the accounting changes.American Banking and Market NewsExicure (XCUR) Projected to Announce Earnings on ThursdayExicure is projected to announce earnings on November 12th, with analysts expecting a loss of $18.60 per share and revenue of $1.64 million. The stock opened at $0.97, and the company holds a consensus 'Sell' rating.Ticker ReportIronwood Pharmaceuticals (NASDAQ:IRWD) and Exicure (NASDAQ:XCUR) Financial ComparisonIronwood Pharmaceuticals and Exicure are compared on financial metrics, with Ironwood beating Exicure on 11 of 15 factors. Ironwood has higher revenue ($296.15M vs $500K) and earnings, and a consensus target price of $6.23 implying 61.69% upside. Exicure is more volatile (beta 3.64) and less profitable.Ticker ReportExicure (NASDAQ:XCUR) & Immatics (NASDAQ:IMTX) Head-To-Head AnalysisImmatics outperforms Exicure on 8 of 14 factors, including a stronger consensus rating and higher institutional ownership. Immatics has a consensus target price of $20.60, implying 177.25% upside, while Exicure's beta is 3.64 versus Immatics' 1.36.American Banking and Market NewsFinancial Review: Exicure (NASDAQ:XCUR) versus Immatics (NASDAQ:IMTX)Immatics and Exicure are compared on valuation, earnings, and analyst ratings. Immatics has a stronger consensus rating, higher institutional ownership, and a lower price-to-earnings ratio, beating Exicure on 8 of 14 factors. Analysts see a 166.49% upside for Immatics.American Banking and Market NewsBioAtla (NASDAQ:BCAB) and Exicure (NASDAQ:XCUR) Head-To-Head ReviewBioAtla and Exicure are compared on profitability, valuation, and analyst ratings. BioAtla beats Exicure on 7 of 13 factors, with a consensus target price of $200 and a potential upside of 15,167.18%. BioAtla is considered more favorable by analysts.Seeking AlphaExicure gets Nasdaq compliance extension (NASDAQ:XCUR)Exicure received a Nasdaq extension through December 2, 2026 to regain compliance with listing rules. The company must maintain at least $2.5M in stockholders' equity, and failure could lead to delisting proceedings, though it can appeal to a Nasdaq Hearings Panel.Markets DailyHead-To-Head Comparison: Exicure (NASDAQ:XCUR) vs. Zealand Pharma A/S (OTCMKTS:ZLDPF)Exicure and Zealand Pharma A/S are compared on earnings, valuation, and analyst ratings. Zealand Pharma A/S has higher revenue ($1.40B vs $500K) and earnings ($977.29M vs -$4.95M), while Exicure trades at a lower P/E. Zealand Pharma A/S beats Exicure on 10 of 14 factors.